Recalls / Class II
Class IID-0307-2023
Product
Milrinone (a) 104MG IN 0.45% NS 130ML,(b) 108MG IN 0.45% NS 135ML, (c) 120MG IN 0.45% NS 150ML, (d) 136MG IN 0.45% NS 170ML, (e) 144MG IN 0.45% NS 180ML, (f) 160MG IN 0.45% NS 200ML, (g) 168MG IN 0.45% NS 210ML, (h) 192MG IN 0.45% NS 240ML, (i) 44MG IN 0.45% NS 55 ML, (j) 52MG IN 0.45% NS 65ML, (k) 56MG IN 0.45% NS 70ML, (l) 68MG IN 0.45% NS 85ML, (m) 84MG IN 0.45% NS 105ML, (n) 88MG IN 0.45% NS 110ML, (o) 92MG IN 0.45% NS 115ML, (p) 96MG IN 0.45% NS 120ML, ionotrop, Rx Only, use with a Curlin or no pump, Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320
- Affected lot / code info
- Beyond Use Date: December 24-31, 2022
Why it was recalled
Lack of sterility assurance
Recalling firm
- Firm
- Sentara Infusion Services
- Notification channel
- Telephone
- Type
- Voluntary: Firm initiated
- Address
- 535 Independence Pkwy Ste 300, N/A, Chesapeake, Virginia 23320-5176
Distribution
- Quantity
- 83 bags
- Distribution pattern
- Dispensed to Patients Nationwide.
Timeline
- Recall initiated
- 2022-12-27
- FDA classified
- 2023-02-15
- Posted by FDA
- 2023-02-22
- Terminated
- 2026-02-20
- Status
- Terminated
Source: openFDA Drug Enforcement endpoint. Recall record D-0307-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.